Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M.
Blood Cancer J. 2024 Jul 8;14(1):108. doi: 10.1038/s41408-024-01084-w.
A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.
Dediu M, Zielinski C.
Breast Care (Basel). 2020 Feb;15(1):67-71. doi: 10.1159/000500620. Epub 2019 May 27.
Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review.
He L, Li H, Wang Y, Li W, Gao L, Xu B, Hu J, He P, Pu W, Sun G, Wang Z, Han Q, Liu B, Chen H.
Front Immunol. 2024 Mar 28;15:1354613. doi: 10.3389/fimmu.2024.1354613. eCollection 2024.
Lupus Nephritis Biomarkers: A Critical Review.
Alduraibi FK, Tsokos GC.
Int J Mol Sci. 2024 Jan 9;25(2):805. doi: 10.3390/ijms25020805.
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz MT, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas JM, Gordon PR, Brüggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H.
Am J Hematol. 2024 Apr;99(4):586-595. doi: 10.1002/ajh.27227. Epub 2024 Feb 5.
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N; CheckMate 816 Investigators.
N Engl J Med. 2025 Aug 21;393(8):741-752. doi: 10.1056/NEJMoa2502931. Epub 2025 Jun 2.
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ Jr, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ Jr, Wolmark N.
N Engl J Med. 2025 Jun 5;392(21):2113-2124. doi: 10.1056/NEJMoa2414859.
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li S, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S.
JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735.
VEXAS syndrome: complete molecular remission after hypomethylating therapy.
Sockel K, Götze K, Ganster C, Bill M, Georgi JA, Balaian E, Aringer M, Trautmann-Grill K, Uhlig M, Bornhäuser M, Haase D, Thiede C.
Ann Hematol. 2024 Mar;103(3):993-997. doi: 10.1007/s00277-023-05611-w. Epub 2024 Jan 12.
Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma.
Lin P, Xie W, Li Y, Zhang C, Wu H, Wan H, Gao M, Liang F, Han P, Chen R, Cheng G, Liu X, Fan S, Huang X.
J Immunother Cancer. 2024 Nov 5;12(11):e009616. doi: 10.1136/jitc-2024-009616.
